No Detail Found!

Qualitative Versus Quantitative PCR in Establishing Response to Chronic Hepatitis C Treatment with Sofosbuvir.

Author(s)
Muhammad Shoaib Siddique Department of Gastroenterology, Memon Medical Institute and Hospital, Karachi, Pakistan
Alvia Saad Department of Emergency, Memon Medical Institute and Hospital, Karachi, Pakistan
Sana Shoaib Department of Medicine, Memon Medical Institute and Hospital, Karachi, Pakistan
Abstract
Objective: To determine the change in rapid virological response for chronic hepatitis C by qualitative PCR testing after treatment with sofosbuvir. Study Design: A descriptive study. Place and Duration of Study: Memon Medical Institute Hospital, Karachi, from January to September 2016. Methodology: The study population consisted of patients above 18 years, till 80 years of age, of both genders, having chronic infection with HCV. Patients included were treatment-naive, non-responders or relapsers; and among these categories, both cirrhotic and non-cirrhotic patients were included. Initially, genotyping and quantitative PCR test was done, one at the start of treatment then at 4 weeks that is till rapid virological response (RVR) was elicited. Qualitative testing was compared by Chi-square with quantitative assays simultaneously to check sensitivity by qualitative testing. Results: Out of 106 patients, the mean age of the patients was 46.40 ±14 years. There were 39 (36.8%) males and 67 (63.2%) females. One hundred (94.3%) were infected with genotype 3. One hundred and five (99.05%) patients responded to sofosbuvir with successful achievement of RVR after 4 weeks. One patient did not achieve RVR (0.94%). The sensitivity of qualitative test was 99%. Conclusion: Qualitative analysis is a cost-effective and sensitive method in patients treated with sofosbuvir for confirming RVR, especially in developing countries where patients are self-paying with significant financial constraints.
Publication Details
Page(s) 188-191
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 3, Year: 2018

Request the full text from PASTIC

References
HepatitisC, 2016.fact sheet N°164",July 2015. Retrieved 4 February -
Mohd HanafiahK,GroegerJ,FlaxmanAD,WiersmaST, 2013.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence,Hepatology 57 1333 -42
SirhindiGA,BajawaMA,AsifMJ,KhanLA,AlamgirMA, 2012.Frequency and different indications for anti-hcv screening,Pak J Med Health Sci 6 94 -6
FerraroD,GiglioM,BonuraC,Di MarcoV,MondelliMU,CraxìA, 2008.Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay,J Viral Hepat 15 66 -70
WilkinsH,MalcolmJK,RainaD,SchadeRR, 2010.Hepatitis C: diagnosis and treatment,Am Fam Physician 81 1351 -7
2013.Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians,MMWR Morb Mortal Wkly Rep 62 362 -5
BoyerTD,MannsMP,SanyalAJ,ZakimD.,Zakim, .Boyer's Hepatology: A Textbook of Liver Disease,pg 107. -
.Hepatitis C Virus (HCV) RNA detection and quantification by real-time reverse transcriptionPCR (RT-PCR), serum clinical information, -
DanielHD,GrantPR,GarsonJA,TedderRS,ChandyGM,AbrahamP, 2008.Quantitation of hepatitis C virus using an in-house real-time reverse transcriptase polymerase chain reaction in plasma samples,DiagnMicrobiol Infect Dis 61 415 -20
MumtazK,HamidSS,MoatterT,AbidS,ShahHA,JafriW., 2008.Distribution of hepatitis C virus genotypes and its response to treatment in Pakistani patients,Saudi Med J 29 1671 -3
ChevaliezS., 2011.Virological tools to diagnose and monitor hepatitis C virus infection,Clin Microbiol Infect 17 116 -21
SpachDH, 2015.Hepatitis C diagnostic testing, -
GuptaE,BajpaiM,ChoudharyA, 2014.Hepatitis C virus: Screening, diagnosis, and interpretation of laboratory assays,Asian J Transfus Sci 8 19 -25
TrianniA,PaneerN,DenkingerC, 2015.High-priority target product profile for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting,FIND 7 1 -42
FirdausR,SahaK,BiswasA,SadhukhanPC, 2015.Current molecular methods for the detection of hepatitis C virus in high risk group population: A systematic review,World J Virol 4 25 -32
DalgardO,BjoroK,Ring-LarsenH,VerbaanH., 2010.In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials,Eur J Gastroenterol Hepatol 22 552 -6
McEwanP,SelvapattN,BrownA,ThurszM,BennettH,WebsterS, 2017.A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective,Eur J Gastroenterol Hepatol 29 208 -14
DiagoM,ShiffmanML,BronowickiJP,ZeuzemS,RodriguezTorresM,PappasSC, 2010.Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin,Hepatology 51 1897 -903
NoellBC,BesurSV, 2015.Changing the face of hepatitis C management - the design and development of sofosbuvir,Drug Des Devel Ther 9 2367 -74
ZhangS,BastianND,GriffinPM, 2015.Cost-effectiveness of sofosbuvirbased treatments for chronic hepatitis C in the US,BMC Gastroenterol 15 98 -
SteinebrunnerN,SprinzlMF,ZimmermannT,WornsMA,ZimmererT,GallePR, 2015.Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort,BMC Gastroenterol 15 97 -
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Engl J Med 368 1878 -87
StedmanC, 2014.Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential,Therap Adv Gastroenterol 7 131 -40
Rodriguez-TorresM,SulkowskiMS,ChungRT,HamzehFM,JensenDM, 2010.Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population,J Viral Hepat 17 139 -147
DalgardO,Martinot-PeignouxM,VerbaanH,BjøroK,RingLarsenH,MarcellinP., 2015.The usefulness of defining rapid virological response by a very sensitive assay (TMA) during treatment of HCV genotype 2/3 infection,PLoSOne 10 e0120866 -
0

Citations

0

Downloads

91

Views